As the Nasdaq hits new record highs and the Federal Reserve's anticipated interest rate decision looms, investors are keeping a close eye on market movements. In this environment, growth companies with strong insider ownership can be particularly appealing, as they often indicate confidence in a firm's long-term potential from those who know it best.
Top 10 Growth Companies With High Insider Ownership In The United States
| Name | Insider Ownership | Earnings Growth |
| Upstart Holdings (UPST) | 12.6% | 93.2% |
| Prairie Operating (PROP) | 31.3% | 86.3% |
| Niu Technologies (NIU) | 37.2% | 92.8% |
| IREN (IREN) | 11.6% | 69% |
| Hippo Holdings (HIPO) | 14.1% | 41.2% |
| Hesai Group (HSAI) | 18.8% | 41.5% |
| FTC Solar (FTCI) | 23.2% | 63% |
| Credo Technology Group Holding (CRDO) | 11.4% | 32.9% |
| Atour Lifestyle Holdings (ATAT) | 21.9% | 23.5% |
| Astera Labs (ALAB) | 12.1% | 36.8% |
We'll examine a selection from our screener results.
Niagen Bioscience (NAGE)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Niagen Bioscience, Inc. is a bioscience company focused on developing healthy aging products with a market cap of $767.23 million.
Operations: The company's revenue is primarily derived from Consumer Products at $84.97 million, Ingredients at $28.21 million, and Analytical Reference Standards and Services at $3.12 million.
Insider Ownership: 29.5%
Revenue Growth Forecast: 17.9% p.a.
Niagen Bioscience has demonstrated significant growth potential, becoming profitable this year with earnings expected to grow substantially above the market average at 26.6% annually. Recent financial results show a strong performance, with Q2 sales increasing from US$22.74 million to US$31.12 million and net income reaching US$3.61 million from a previous loss. The company raised its revenue growth guidance for 2025 and secured an exclusive license agreement for Parkinson's treatment development, underscoring its strategic expansion into regulated drug development.
- Click here to discover the nuances of Niagen Bioscience with our detailed analytical future growth report.
- Insights from our recent valuation report point to the potential undervaluation of Niagen Bioscience shares in the market.
Cadre Holdings (CDRE)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Cadre Holdings, Inc. manufactures and distributes safety equipment and related products for protection in hazardous situations both in the United States and internationally, with a market cap of approximately $1.28 billion.
Operations: The company's revenue segments consist of $503.28 million from Product and $104.99 million from Distribution.
Insider Ownership: 29.1%
Revenue Growth Forecast: 10.3% p.a.
Cadre Holdings exhibits growth potential with earnings projected to grow at 21.9% annually, outpacing the US market. Despite no substantial insider buying recently, more shares were bought than sold in the past three months, indicating confidence from insiders. The company trades at a significant discount to its estimated fair value and expects annual sales between US$624 million and US$630 million for 2025. However, its debt coverage by operating cash flow remains weak.
- Click to explore a detailed breakdown of our findings in Cadre Holdings' earnings growth report.
- Upon reviewing our latest valuation report, Cadre Holdings' share price might be too optimistic.
Tuya (TUYA)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Tuya Inc. operates as an AI cloud platform service provider in the People’s Republic of China, with a market cap of approximately $1.52 billion.
Operations: The company's revenue primarily comes from its Internet Software & Services segment, which generated $318.49 million.
Insider Ownership: 29.8%
Revenue Growth Forecast: 10.8% p.a.
Tuya's earnings are forecast to grow at 22.3% annually, surpassing the US market average of 15.3%, despite revenue growth expectations being more modest at 10.8% per year. The company has recently turned profitable, reporting a net income of US$12.59 million for Q2 2025 compared to US$3.13 million a year ago. Although the dividend yield is attractive at 4.11%, it is not well covered by earnings or free cash flows, which could be a concern for sustainability.
- Take a closer look at Tuya's potential here in our earnings growth report.
- In light of our recent valuation report, it seems possible that Tuya is trading beyond its estimated value.
Seize The Opportunity
- Explore the 196 names from our Fast Growing US Companies With High Insider Ownership screener here.
- Ready To Venture Into Other Investment Styles? Uncover the next big thing with financially sound penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if Niagen Bioscience might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com